US to pay Pfizer nearly $2bn for COVID-19 vaccine supply
23-07-2020
Gilead agrees 127-country remdesivir licence with generic makers
14-05-2020
Taljat David / Shutterstock.com
China’s Junshi Biosciences has licensed technology to produce an antibody against COVID-19 from Swiss biotechnology firm Lonza.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Junshi Biosciences, Lonza, antibody, COVID-19, vaccine, gene expression, GS Xceed, remdesivir, antiviral, Gilead, licence
